1
EXHIBIT 11.1
GENOME THERAPEUTICS CORP. AND SUBSIDIARIES
CALCULATION OF SHARES USED IN DETERMINING
PRIMARY NET INCOME (LOSS) PER SHARE
YEAR ENDED AUGUST 31,
1994 1995 1996
-------------------------------------
Weighted average common stock outstanding
during the year 11,097,224 12,287,918 15,530,639
Weighted average common stock equivalents
outstanding during the year -- 673,816 2,599,155
-------------------------------------
11,097,224 12,961,734 18,129,794
=====================================
CALCULATION OF SHARES USED IN DETERMINING
FULLY DILUTED NET INCOME (LOSS) PER SHARE
YEAR ENDED AUGUST 31,
1994 1995 1996
-------------------------------------
Weighted average common stock outstanding
during the year 11,097,224 12,287,918 15,530,639
Weighted average common stock equivalents
outstanding during the year -- 748,823 2,599,155
-------------------------------------
11,097,224 13,036,741 18,129,794
=====================================